Experience in the use of a synthetic analogue of GLP-2 in a patient with short bowel syndrome in the Republic of Bashkortostan

   Background. Short bowel syndrome, or short intestine, as a rule, is a consequence of extensive intestinal resection, usually of the iliac and skinny sections, when no more than 115-200 cm remains from the original length (on average in the population of 6.5 meters). Short bowel syndrome is not so much anatomical as functional, since clinical manifestations are often they depend on both the residual length and the level of the lost fragment, the safety of the ileocecal valve, comorbid conditions and the age of the patient. The lethality of such conditions is kept at a high level, due to the loss of the organ of absorption of nutrients and fluid, the rapid development of severe intestinal insufficiency and electrolyte decompensation. Currently, the issue of tactics for managing such patients remains open, clinical studies are actively continuing, new drugs for treatment are being registered, new approaches and the need for routing regulation in order to reduce mortality are emerging.

   Objective. This article was written with the aim of evaluating modern methods of treating patients with short bowel syndrome using the example of a clinical case described in the Republic of Bashkortostan.

   Results. In a patient diagnosed with: "Other intestinal malabsorption: short bowel syndrome, ultrashort variant (35 cm after bowel reconstruction) in the presence of a large intestine. Condition after repeated operations, including autologous reconstruction of the intestine, the use of the drug teduglutide led to an improvement in the processes of adaptation of the residual fragment of the intestine. For 5 years, the patient gained weight, a decrease in the frequency of bowel movements and a decrease in stool volume were recorded. A decrease in dependence on parenteral nutrition was noted. In addition, the patient noted a good tolerability of the treatment and a significant improvement in well-being. Thus, a comprehensive multidisciplinary approach, as well as rational management of patients with short bowel syndrome, can significantly improve the quality of life of patients suffering from this disease.

1. Sosnovskaya Ye. V. Modern possibilities of pharmacotherapy of patients with short bowel syndrome. Vestnik SurGU. Meditsina. 2021; 4 (50). (In Russ.)

2. Aver'yanova Yu. V., Razumovskiy A. Yu., Makarov S. P., Petrov D. A., Bryusov G. P., Kochkin V. S., Stepanov A. E. Modern strategy for the treatment of children with short bowel syndrome: 12 years of experience. Anesteziologiya i reanimatologiya. 2018; 6: 67-74. doi: 10.17116/anaesthesiology201806167. (In Russ.)

3. Schwartz L. K., O’Keefe S. J. D., Fujioka K., et al. Long-term Teduglutide for the Treatment of Patients with Intestinal Failure Associated with Short Bowel Syndrome. Clin Transl Gastroenterol. 2016. Vol. 7, Is. 2. Р. e142. DOI: 10.1038/ctg.2015.69.

4. Khasanov R. R., Khagl' K. I., Vessel' L. M. Review of surgical methods for the treatment of short bowel syndrome. Rossiyskiy vestnik detskoy khirurgii, anesteziologii i reanimatologii. 2014; 3 (4): 14-20. EDN: SWMGPL. (In Russ.)

5. Aver'yanova Yu. V., Vessel' L., Yerpuleva Yu. V., Nikolayev V. V., Stepanov A. E., Chubarova A. I., Shchukin V. V., Khasanov R. R. Federal clinical guidelines "Treatment of children with short bowel syndrome". Rossiyskiy vestnik detskoy khirurgii, anesteziologii i reanimatologii. 2014; 4 (4): 92-108. EDN: RKUCKQ. (In Russ.)

6. Sukhotnik I. G. Short bowel syndrome in children. Rossiyskiy vestnik detskoy khirurgii, anesteziologii i reanimatologii. 2017; (3): 99-116. EDN: ZXHMTN. (In Russ.)

7. Ba'ath M. E., Almond S., King B., Bianchi A., Khalil B. A., Morabito A. Short bowel syndrome: a practical pathway leading to successful enteral autonomy. World J Surg. 2012; 36 (5): 1044-1048. DOI: 10.1007/s00268-012-1512-5